A multicentre, prospective, randomised controlled study of efficacy and safety of decitabine combination with low dose CAG in patients with myelodysplastic syndrome.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Apr 2016

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Aclarubicin (Primary) ; Cytarabine (Primary) ; Decitabine (Primary) ; Granulocyte colony-stimulating factors (Primary)
Indications Myelodysplastic syndromes
Focus Therapeutic Use

21 May 2012 Planned end date 15 Oct 2015 added as reported by Chinese Clinical Trial Register.
25 Nov 2011 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com